Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.58 |
| ▸ | JAK2 | O60674 | 3/20 | 0.58 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | CLK2 | P49760 | 2/20 | 0.51 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | FER | P16591 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | MARK3 | P27448 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7371874 | 0.80 | MAP2K4 (0.50) | FADS1CHEK1HPGDMAPK1 | |
| SCHEMBL7371869 | 0.79 | JAK2 (0.33) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL11766927 | 0.79 | MAT2A (0.46) | JAK2HTR2AHTR2BFADS1SLC6A4 | |
| SCHEMBL21341662 | 0.76 | KIF11 (0.44) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL182633 | 0.76 | JAK2 (0.63) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL2300691 | 0.76 | PDPK1 (0.63) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL30855645 | 0.75 | PDPK1 (0.68) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL628641 | 0.75 | MAP2K4 (0.52) | FADS1GSK3BMETAP2CHUKMAPK1 | |
| Hydrochloric Acid SCHEMBL730582 | 0.74 | JAK2 (0.61) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL4972056 | 0.73 | KDM4E (0.52) | PDPK1FLT3FADS1FGFR1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387965-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-118019735-A | Arylsulfonyl compounds as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | PDPK1 84/4885JAK2 356/4885FLT3 527/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | PDPK1 84/4885JAK2 356/4885FLT3 527/4885 |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CCR6, CCR1, CCR3 | PDPK1 3065/4885JAK2 216/4885FLT3 1073/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | PDPK1 58/4885JAK2 2/4885FLT3 556/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | PDPK1 70/4885JAK2 2/4885FLT3 753/4885 |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | PDPK1 3065/4885JAK2 216/4885FLT3 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.